Ceftriaxone Dosing for Typhoid Fever
For uncomplicated typhoid fever, use ceftriaxone 2-4 grams IV once daily for adults and 75 mg/kg IV once daily (maximum 4 grams) for children, administered for 7-14 days. 1
Adult Dosing
The FDA-approved dosing for adults is 1-2 grams IV once daily, with a maximum of 4 grams per day 1. However, clinical trials in typhoid fever have consistently used 3-4 grams daily for adults 2, 3. The higher dose (3-4 grams) is supported by research demonstrating efficacy in bacteremic typhoid fever 2, 4.
- Standard dose: 2 grams IV once daily
- Severe infection: 3-4 grams IV once daily
- Duration: 7-14 days (most studies used 5-7 days successfully) 2, 4, 3
Pediatric Dosing
75 mg/kg IV once daily (maximum 4 grams) is the established dose for children 1, 2, 3, 5, 6. This dose has been validated across multiple clinical trials with cure rates of 79-97% 3, 5.
Special Considerations for Neonates
Ceftriaxone is contraindicated in premature neonates and in term neonates ≤28 days requiring calcium-containing IV solutions 1. If used in neonates, administer over 60 minutes (not 30 minutes) to reduce risk of bilirubin encephalopathy 1.
Administration Details
- IV infusion over 30 minutes for adults and children (60 minutes for neonates) 1
- Concentration: 10-40 mg/mL recommended 1
- Do NOT mix with calcium-containing solutions (Ringer's, Hartmann's) - precipitation will occur 1
Duration of Therapy
While the FDA label states 4-14 days for general infections 1, clinical trials in typhoid fever demonstrate:
- 5-7 days is adequate for uncomplicated cases 4, 3, 6
- 7-14 days for complicated or severe infections 2
- Continue for at least 2 days after defervescence 1
Clinical Performance Expectations
Important caveat: Ceftriaxone has slower bactericidal activity than fluoroquinolones 7. Expect:
- Mean defervescence time: 3-4 days 4, 6
- Some patients may remain febrile for 9-13 days despite successful treatment 3
- Blood cultures clear rapidly (typically negative by day 3) 3
- No post-antibiotic effect detected, unlike fluoroquinolones 7
This slower clinical response does NOT indicate treatment failure - it reflects the drug's pharmacodynamics 7. Do not prematurely switch antibiotics if the patient remains febrile beyond 5-7 days but is otherwise improving.
Resistance Considerations
Ceftriaxone remains effective against most S. typhi strains, including those with fluoroquinolone resistance 8. However, extensively drug-resistant (XDR) strains emerging in Pakistan may require alternative therapy with azithromycin and/or meropenem 9. Local resistance patterns should guide initial therapy 9, 8.
Comparative Efficacy
Based on systematic review evidence 8:
- Versus azithromycin: Ceftriaxone may have lower clinical failure rates and faster defervescence
- Versus fluoroquinolones: Similar cure rates when susceptibility is maintained, but slower clinical response
- Cure rates: 79-97% across multiple trials 2, 4, 3, 5
No dosage adjustment needed for renal or hepatic impairment up to 2 grams daily 1.